BlackRock Fund Advisors has recently announced that it has increased stake in Xeris Biopharma Holdings Inc (NASDAQ:XERS) by 0.67%. After grabbing 8.4 million shares, the institutional investor is now in possession of 56076.0 shares of the Healthcare Company. The new investment brought the stake of investor firm to 6.08% having worth around $15.63 million. Moreover, The Vanguard Group, Inc. increased its share by 69774.0 to have a control over 6.76 million shares. And Stonepine Capital Management LLC raised its holdings to 0.42 million shares by acquiring 5.92 million shares or 4.28% of the stake.
Xeris Biopharma Holdings Inc (XERS) concluded trading on 01/10/24 at a closing price of $2.80, with 11.31 million shares of worth about $31.68 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 16.67% during that period and on Wednesday the price saw a gain of about 16.18%. Currently the company’s common shares owned by public are about 136.27M shares, out of which, 129.49M shares are available for trading.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 18 times over the past 12 months. They bought 3,286,139 shares in 18 of the transactions. In 0 selling transactions, insiders dumped 0 shares.
Vanguard Total Stock Market ETF, iShares Russell 2000 ETF, and Vanguard Extended Market Index Fu are the top 3 mutual funds which are holding stakes in Xeris Biopharma Holdings Inc Vanguard Total Stock Market ETF is currently holding 4.11 million shares of worth totaling $7.64 million. The company recently came buying 0.0 shares which brought its stake up to 2.97% of the company’s outstanding shares. iShares Russell 2000 ETF bought 1581.0 shares, after which its hold over company’s outstanding shares expand to 2.33%, leaving 3.21 million shares with the mutual fund that have a worth of about $5.98 million. Vanguard Extended Market Index Fu, after buying 1.99 million shares, have now control over 1.44% of the stake in the company. It holds 0.0 shares of worth $3.7 million.
Xeris Biopharma Holdings Inc (NASDAQ: XERS) started trading at $2.78, above $0.37 from concluding price of the previous day. However, the stock later moved at a day high price of 2.8100, or with a gain of 16.18%. Stock saw a price change of 25.00% in past 5 days and over the past one month there was a price change of 37.93%. Year-to-date (YTD), XERS shares are showing a performance of 19.15% which increased to 154.55% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.06 but also hit the highest price of $3.07 during that period. The average intraday trading volume for Xeris Biopharma Holdings Inc shares is 1.47 million. The stock is currently trading 27.53% above its 20-day simple moving average (SMA20), while that difference is up 43.03% for SMA50 and it goes to 26.99% higher than SMA200.
BlackRock Fund Advisors acquired 8.4 million shares of Xeris Biopharma Holdings Inc having value of about $15.63 million. Data submitted at the U.S SEC by BlackRock Fund Advisors revealed that the firm now holds 56076.0 shares in the company valued at close to $157012.8, or have control over 0.67% stake in the company. Xeris Biopharma Holdings Inc (NASDAQ: XERS) currently have 136.27M outstanding shares and institutions hold larger chunk of about 39.05% of that. Holding of mutual funds in the company is about 23.83% while other institutional holders and individual stake holders have control over 3.82% and 15.25% of the stake respectively.
The stock has a current market capitalization of $386.74M and its 3Y-monthly beta is at 1.57. It has posted earnings per share of -$0.45 in the same period. It has Quick Ratio of 1.38 while making debt-to-equity ratio of 58.90. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for XERS, volatility over the week remained 7.65% while standing at 7.00% over the month.
Analysts are in expectations that Xeris Biopharma Holdings Inc (XERS) stock would likely to be making an EPS of -$0.1 in the current quarter, while forecast for next quarter EPS is -$0.09 and it is -$0.29 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.13 which is -$0.07 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.1 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 43.89% while it is estimated to increase by 37.46% in next year.
Analysts at 5 brokerage firms have issued recommendations for the Xeris Biopharma Holdings Inc (XERS)’s stock and average of those rates the stock at a “Strong Buy” and assign it a score of 1.00. Out of those 5 Wall Street analysts, 5 recommended a “Buy” rating, while 0 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Craig Hallum on August 28, 2023 offering a Buy rating for the stock and assigned a target price of $4.50 to it.
